Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 9/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.54 |
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.51 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | IL2 | P60568 | 4/20 | 0.49 |
| ▸ | STK17B | O94768 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL18129762 | 0.95 | KIT (0.49) | KITDYRK1AMAP4K1AAK1SLC2A1 | |
| SCHEMBL18129805 | 0.90 | KIT (0.60) | KITDYRK1AMAP4K1AAK1SLC2A1 | |
| SCHEMBL18129508 | 0.89 | DYRK1A (0.55) | KITDYRK1AMAP4K1AAK1SLC2A1 | |
| SCHEMBL18129527 | 0.87 | KIT (0.59) | KITDYRK1AMAP4K1AAK1SLC2A1 | |
| SCHEMBL18129496 | 0.87 | CCNT1 (0.56) | KITDYRK1AMAP4K1AAK1SLC2A1 | |
| SCHEMBL18129573 | 0.85 | DYRK1A (0.52) | KITDYRK1AMAP4K1AAK1SLC2A1 | |
| SCHEMBL18129798 | 0.84 | KIT (0.55) | KITDYRK1AMAP4K1AAK1SLC2A1 | |
| SCHEMBL18129476 | 0.84 | KIT (0.55) | KITDYRK1AMAP4K1AAK1SLC2A1 | |
| SCHEMBL18129459 | 0.84 | AAK1 (0.53) | KITDYRK1AMAP4K1AAK1SLC2A1 | |
| SCHEMBL18129747 | 0.83 | MAP4K1 (0.55) | KITDYRK1AMAP4K1AAK1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-03-26 | — | — | US | disclosed |
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TANK, NFKBIA, TBK1 | KIT 869/4885DYRK1A 1134/4885MAP4K1 766/4885 |
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | NFKBIA, TANK, TBK1 | KIT 1122/4885DYRK1A 1148/4885MAP4K1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.